To Screen or Not to Screen (for Skin Cancer) – Reframing the Question
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 29 July 2016
To screen or not to screen actually isn’t the question While an adaptation of Hamlet’s famous phrase may capture the headlines on whole-body skin checks, a deeper dive gets us closer to questions of life and death.
Highlights from the National Cancer Moonshot Summit
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 7 July 2016 In Events, News
The National Cancer Moonshot was announced by President Obama in his State of the Union Address in January 2016 and VP Biden was charged with spearheading the effort. Few would disagree with Mr. Biden’s selection as leader given the personal experience he and his family endured with the loss of...
Understanding Immunotherapy Part 3: CTLA-4
Now that you’ve read our background on immunotherapy and learned about PD-1, it’s time to focus on another protein that plays a key role in cancer development, CTLA-4. What is CTLA-4? In addition to displaying PD-1 on the cell surface, T cells also display CTLA-4.
Research Q&A: Dr. Tim Bullock
21 March 2016 In Science
In the latest blog post, we chatted with the University of Virginia’s Tim Bullock, Ph.D., a tumor immunologist in the Pathology Department and MRA-funded investigator. Read on to learn what he has to say about melanoma research and prevention efforts.
Understanding Immunotherapy Part 2: PD-1
Now that we’ve provided a brief background on immunotherapy, it’s time to dive more deeply into the subject. In the second installment of this blog series, we’ll be examining PD-1, a protein that plays a crucial role in cancer’s ability to hide from our immune systems. What is PD-1? PD-1...
Researcher Q&A: Dr. John D’Orazio
7 January 2016 In Science
In the latest blog post, we chatted with the University of Kentucky’s John D’Orazio, M.D., Ph.D., a pediatric hematologist oncologist, and a 2015 MRA grant awardee. Read on to learn what he has to say about melanoma research and prevention efforts.